252eP Temozolomide–irinotecan (TEMIRI) protocol in adult patients with relapsed/refractory Ewing sarcoma: A single-center experience
ESMO Rare Cancers · 2026-03 · 5 · 100458
DOI: 10.1016/j.esmorc.2026.100458 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von B. Zivkovic und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zivkovic, B., Lukic, V., Djurdjevic, D., Mijucic, J., & Ristic, D. (2026). 252eP Temozolomide–irinotecan (TEMIRI) protocol in adult patients with relapsed/refractory Ewing sarcoma: A single-center experience. ESMO Rare Cancers, 5, 100458. https://doi.org/10.1016/j.esmorc.2026.100458
Vancouver
Zivkovic B, Lukic V, Djurdjevic D, Mijucic J, Ristic D. 252eP Temozolomide–irinotecan (TEMIRI) protocol in adult patients with relapsed/refractory Ewing sarcoma: A single-center experience. ESMO Rare Cancers. 2026;5:100458. doi:10.1016/j.esmorc.2026.100458
BibTeX
@article{Zivkovic2026,
author = {Zivkovic, B. and Lukic, V. and Djurdjevic, D.A. and Mijucic, J. and Ristic, D.},
title = {252eP Temozolomide–irinotecan (TEMIRI) protocol in adult patients with relapsed/refractory Ewing sarcoma: A single-center experience},
journal = {ESMO Rare Cancers},
year = {2026},
volume = {5},
pages = {100458},
doi = {10.1016/j.esmorc.2026.100458}
}
EUVIMED